Document is current
Any future updates will be listed below
-
Authors
Kanno, Atsuo
Kito, Takuya https://orcid.org/0009-0009-9355-3870
Maeda, Masashi
Yamaki, Shanni
Amano, Yasushi https://orcid.org/0000-0002-7190-7537
Shimomura, Takuya https://orcid.org/0000-0002-6769-4655
Anisimova, Margarita
Kanazawa, Naomi https://orcid.org/0000-0001-8027-4447
Suzuki, Koichiro
Razai, Amir
Mihara, Takuma
Kubo, Kaori
Shimada, Takeshi
Nakamura, Koji
Nomura, Naoko
Kondo, Yuji
Okimoto, Akira https://orcid.org/0000-0003-3115-2800
Sugiyama, Azusa
Park, Deborah
Stein, Ivar
Petshow, Samuel
Vandendoren, Valentin https://orcid.org/0009-0005-9099-4495
Bilic, Sanela
Kazimi, Roghiye
Eastman, Vallari
Snipas, Scott J.
Mitchell, Mathew https://orcid.org/0009-0007-5717-8634
Maurer, Mari
Jefson, Marty
Lichter, Jay
Yamajuku, Daisuke
Shirai, Hiroki https://orcid.org/0009-0004-1019-6120
Adachi, Megumi https://orcid.org/0000-0003-3404-6640
Hoeppner, Daniel J. https://orcid.org/0000-0002-0886-5215
Kubo, Satoshi
Zito, Karen
Iizuka, Takahiro https://orcid.org/0000-0002-7234-0720
Flynn, Peter
Matsumoto, Mitsuyuki https://orcid.org/0000-0002-1172-2354
-
Funding
Funding for this research was provided by:
Astellas Pharma (N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A)
Arialys Therapeutics, Inc.
- License Information
-
More Information
Article History
Received: 8 August 2024
Accepted: 23 May 2025
First Online: 17 June 2025
Competing interests
: A.K., M.Maeda, S.K., and S.B. are consultants, and S.Y., A.R., R.K., V.E., S.J.S., M.Mitchell, M.Maurer, M.J., J.L., P.F., and M.Matsumoto are full-time employees of Arialys Therapeutics., Inc. A.K., T.K., M.Maeda, Y.A., T.Shimomura, T.M., K.K., T.Shimada, K.N., N.N., Y.K., A.S., D.Y., M.Adachi, and D.J.H. are full-time employees of Astellas Pharma Inc. K.S., A.O., H.S., and M.Matsumoto were full-time employees of Astellas Pharma Inc. at the time the part of research was conducted, but are no longer affiliated with the company. V.V. and S.B. are full-time employees of Vanadro, LLC. K.Z. and T.I. received grant support from Astellas Pharma, Inc. The remaining authors declare no competing interests. ART5803 was originally developed by Astellas Pharma, Inc. ART5803 was subsequently acquired from Astellas by Arialys Therapeutics, Inc. via the execution of an exclusive worldwide licensing agreement. Arialys further developed the asset, including work within this manuscript, and is now conducting clinical studies. The work described in this manuscript was therefore conducted under the control of either Astellas or Arialys.
